We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
Solventum targets about $500M in annual savings from its Transform for the Future program.
SOLV posted roughly 4% normalized organic growth in Q2, supported by strength across its three segments.
Solventum plans nearly 20 product launches through Q1 2028, while raw material costs pose margin risk.
Solventum Corporation (SOLV - Free Report) is well-poised for growth in the coming quarters, driven by strong demand across its business segments, supported by continued investment in innovation, R&D and digital capabilities. The optimism, led by a solid second-quarter 2026 performance and a solid restructuring program, is expected to contribute further. However, concerns regarding the rise in raw material costs persist.
In the year-to-date period, this Zacks Rank #3 (Hold) company’s shares have gained 12.1% compared with the industry’s 3.9% growth. The S&P 500 increased 10.6% in the same time frame.
The renowned global healthcare solutions provider has a market capitalization of $15.33 billion. The company projects 18.3% earnings growth for 2026 and expects to maintain its strong performance going forward. Solventum’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 13.2%.
Let’s delve deeper.
Image Source: Zacks Investment Research
Key Drivers of SOLV Stock
Future Cost Transformation Program: Solventum’s “Transform for the Future” program targets about $500 million of annual cost savings through operational efficiencies, system streamlining and automation, with most benefits expected in 2027 and beyond. In 2026, management is still targeting operating margin expansion of 50 to 100 basis points despite higher tariff costs, reflecting sales leverage, programmatic savings and portfolio actions. Separation execution is also progressing.
By second-quarter 2026, Solventum had exited nearly 70% of roughly 200 transition service agreements and migrated about 950 of 1,200 systems. Management remains on pace to exit 90% of transition service agreements by 2026-end and expects separation costs to decline beginning in the fourth quarter.
Strategic Growth Drivers: Solventum continues to execute on its long-term growth strategy, with management expecting five key growth drivers to contribute more than 80% of future expansion. The company delivered roughly 4% normalized organic growth in second-quarter 2026 after adjusting for ERP advance orders and SKU exits. Within MedSurg, Advanced Wound Care rose 7.1% organically, supported by strong demand for V.A.C. Peel and Place, Prevena and Acera, while Tegaderm CHG adoption, sterilization assurance products and recent Attest launches continued to strengthen the business.
The company is also accelerating innovation, with nearly 20 new product launches planned through first-quarter 2028, including MedSurg launches in early 2027 and dental aesthetics products later this year. Dental Solutions posted 15.2% organic growth in the quarter, driven by products such as Clarity Aligners and Filtek innovations, while Health Information Systems grew 5.4% organically on strength in revenue cycle management, autonomous coding and international expansion. The planned separation of the HIS business is expected to sharpen Solventum's focus on its higher-growth MedSurg and Dental franchises.
Solid Q2 Results:Solventum delivered a strong second-quarter 2026, with earnings and revenues surpassing the Zacks Consensus Estimate. Performance benefited from healthy demand, new product launches and stronger commercial execution across all three segments. MedSurg gained from negative pressure wound therapy and antimicrobial IV-site management products. Dental Solutions benefited from restorative and aesthetics offerings, while HIS maintained momentum in revenue cycle management.
Downsides of SOLV Stock
Potential Raw Material Cost Step-Up From 3M Supply Agreement: Solventum disclosed that under its long-term supply agreement with 3M, the supplier holds a contractual option in 2027 to increase the cost of certain raw materials supplied. If this option is exercised, it could create a 100-basis-point margin headwind.
The company emphasized that it is actively working with 3M to explore alternatives that could avoid this outcome. SOLV owns the intellectual property rights for these materials within its field of use, meaning it has the option to source the materials from other chemical manufacturers if necessary.
SOLV has been witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings per share (EPS) has remained stable at $7.23.
The Zacks Consensus Estimate for the company’s third-quarter revenues is pegged at $1.94 billion, implying a 7.7% decline from the year-ago quarter’s reported number.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
Key Takeaways
Solventum Corporation (SOLV - Free Report) is well-poised for growth in the coming quarters, driven by strong demand across its business segments, supported by continued investment in innovation, R&D and digital capabilities. The optimism, led by a solid second-quarter 2026 performance and a solid restructuring program, is expected to contribute further. However, concerns regarding the rise in raw material costs persist.
In the year-to-date period, this Zacks Rank #3 (Hold) company’s shares have gained 12.1% compared with the industry’s 3.9% growth. The S&P 500 increased 10.6% in the same time frame.
The renowned global healthcare solutions provider has a market capitalization of $15.33 billion. The company projects 18.3% earnings growth for 2026 and expects to maintain its strong performance going forward. Solventum’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 13.2%.
Let’s delve deeper.
Image Source: Zacks Investment Research
Key Drivers of SOLV Stock
Future Cost Transformation Program: Solventum’s “Transform for the Future” program targets about $500 million of annual cost savings through operational efficiencies, system streamlining and automation, with most benefits expected in 2027 and beyond. In 2026, management is still targeting operating margin expansion of 50 to 100 basis points despite higher tariff costs, reflecting sales leverage, programmatic savings and portfolio actions. Separation execution is also progressing.
By second-quarter 2026, Solventum had exited nearly 70% of roughly 200 transition service agreements and migrated about 950 of 1,200 systems. Management remains on pace to exit 90% of transition service agreements by 2026-end and expects separation costs to decline beginning in the fourth quarter.
Strategic Growth Drivers: Solventum continues to execute on its long-term growth strategy, with management expecting five key growth drivers to contribute more than 80% of future expansion. The company delivered roughly 4% normalized organic growth in second-quarter 2026 after adjusting for ERP advance orders and SKU exits. Within MedSurg, Advanced Wound Care rose 7.1% organically, supported by strong demand for V.A.C. Peel and Place, Prevena and Acera, while Tegaderm CHG adoption, sterilization assurance products and recent Attest launches continued to strengthen the business.
The company is also accelerating innovation, with nearly 20 new product launches planned through first-quarter 2028, including MedSurg launches in early 2027 and dental aesthetics products later this year. Dental Solutions posted 15.2% organic growth in the quarter, driven by products such as Clarity Aligners and Filtek innovations, while Health Information Systems grew 5.4% organically on strength in revenue cycle management, autonomous coding and international expansion. The planned separation of the HIS business is expected to sharpen Solventum's focus on its higher-growth MedSurg and Dental franchises.
Solid Q2 Results:Solventum delivered a strong second-quarter 2026, with earnings and revenues surpassing the Zacks Consensus Estimate. Performance benefited from healthy demand, new product launches and stronger commercial execution across all three segments. MedSurg gained from negative pressure wound therapy and antimicrobial IV-site management products. Dental Solutions benefited from restorative and aesthetics offerings, while HIS maintained momentum in revenue cycle management.
Downsides of SOLV Stock
Potential Raw Material Cost Step-Up From 3M Supply Agreement: Solventum disclosed that under its long-term supply agreement with 3M, the supplier holds a contractual option in 2027 to increase the cost of certain raw materials supplied. If this option is exercised, it could create a 100-basis-point margin headwind.
The company emphasized that it is actively working with 3M to explore alternatives that could avoid this outcome. SOLV owns the intellectual property rights for these materials within its field of use, meaning it has the option to source the materials from other chemical manufacturers if necessary.
Solventum Corporation Price
Solventum Corporation price | Solventum Corporation Quote
Trend in Estimate Revision
SOLV has been witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings per share (EPS) has remained stable at $7.23.
The Zacks Consensus Estimate for the company’s third-quarter revenues is pegged at $1.94 billion, implying a 7.7% decline from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.